Correlation Between Lipum AB and Ascelia Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lipum AB and Ascelia Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lipum AB and Ascelia Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lipum AB and Ascelia Pharma AB, you can compare the effects of market volatilities on Lipum AB and Ascelia Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lipum AB with a short position of Ascelia Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lipum AB and Ascelia Pharma.

Diversification Opportunities for Lipum AB and Ascelia Pharma

0.58
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Lipum and Ascelia is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Lipum AB and Ascelia Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ascelia Pharma AB and Lipum AB is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lipum AB are associated (or correlated) with Ascelia Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ascelia Pharma AB has no effect on the direction of Lipum AB i.e., Lipum AB and Ascelia Pharma go up and down completely randomly.

Pair Corralation between Lipum AB and Ascelia Pharma

Assuming the 90 days trading horizon Lipum AB is expected to generate 1.43 times more return on investment than Ascelia Pharma. However, Lipum AB is 1.43 times more volatile than Ascelia Pharma AB. It trades about 0.07 of its potential returns per unit of risk. Ascelia Pharma AB is currently generating about -0.01 per unit of risk. If you would invest  1,300  in Lipum AB on December 31, 2024 and sell it today you would earn a total of  190.00  from holding Lipum AB or generate 14.62% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Lipum AB  vs.  Ascelia Pharma AB

 Performance 
       Timeline  
Lipum AB 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Lipum AB are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Lipum AB unveiled solid returns over the last few months and may actually be approaching a breakup point.
Ascelia Pharma AB 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Over the last 90 days Ascelia Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable technical and fundamental indicators, Ascelia Pharma is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Lipum AB and Ascelia Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lipum AB and Ascelia Pharma

The main advantage of trading using opposite Lipum AB and Ascelia Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lipum AB position performs unexpectedly, Ascelia Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascelia Pharma will offset losses from the drop in Ascelia Pharma's long position.
The idea behind Lipum AB and Ascelia Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device